Metformin Enhances Autophagy and Provides Cardioprotection in &dgr;-Sarcoglycan Deficiency-Induced Dilated Cardiomyopathy

Background: Metformin is a popular antidiabetic agent that is also used to treat heart failure patients with type 2 diabetes mellitus. Several reports suggest that metformin may also have cardioprotective effects in patients without diabetes mellitus. In the present study, we investigated the possible therapeutic effect of metformin in heart failure and its underlying molecular mechanisms using a &dgr;-sarcoglycan-deficient mouse model of dilated cardiomyopathy. Methods and Results: Thirty-two-week-old &dgr;-sarcoglycan-deficient mice exhibiting established cardiomyopathy with extensive left ventricular dilatation and dysfunction were administered saline or metformin (200 mg/kg per day) for 4 weeks using osmotic mini-pumps. Metformin partially reversed the left ventricular dilatation (reverse remodeling) and significantly improved cardiac function. The hearts of metformin-treated mice showed less fibrosis, less cardiomyocyte hypertrophy, and fewer degenerative subcellular changes than saline-treated mice. These effects were accompanied by restored expression of the sarcomeric proteins myosin heavy chain and troponin I, and their transcription factor, GATA-4. Autophagy was enhanced in the hearts from metformin-treated mice, as indicated by increase of myocardial microtubule-associated protein-1 LC-3 (light chain 3)-II levels and LC3-II/-I ratios as well as levels of cathepsin D and ATP. In addition, increased numbers of autophagic vacuoles and lysosomes were accompanied increased AMP-activated protein kinase activity and suppression of mammalian target of rapamycin phosphorylation. Finally, autophagic flux assays using short-term chloroquine treatment revealed that autophagy was activated in &dgr;-sarcoglycan-deficient hearts and was further augmented by metformin treatment. Conclusions: Metformin is a beneficial pharmacological tool that mitigates heart failure caused by &dgr;-sarcoglycan deficiency in association with enhanced autophagy.

[1]  Qiang Wu,et al.  Metformin Activates the AMPK-mTOR Pathway by Modulating lncRNA TUG1 to Induce Autophagy and Inhibit Atherosclerosis , 2020, Drug design, development and therapy.

[2]  H. Bøtker,et al.  Translational issues for mitoprotective agents as adjunct to reperfusion therapy in patients with ST‐segment elevation myocardial infarction , 2020, Journal of cellular and molecular medicine.

[3]  A. Natali,et al.  Metformin effects on the heart and the cardiovascular system: A review of experimental and clinical data. , 2017, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[4]  L. Galluzzi,et al.  Autophagy and Mitophagy in Cardiovascular Disease. , 2017, Circulation research.

[5]  B. Jasmin,et al.  Metformin increases peroxisome proliferator–activated receptor γ Co‐activator‐1α and utrophin a expression in dystrophic skeletal muscle , 2015, Muscle & nerve.

[6]  M. Seishima,et al.  Autophagic adaptations in diabetic cardiomyopathy differ between type 1 and type 2 diabetes , 2015, Autophagy.

[7]  B. Jasmin,et al.  Utrophin A is essential in mediating the functional adaptations of mdx mouse muscle following chronic AMPK activation. , 2015, Human molecular genetics.

[8]  B. Viollet,et al.  Metformin Protects Against Systolic Overload–Induced Heart Failure Independent of AMP-Activated Protein Kinase &agr;2 , 2014, Hypertension.

[9]  D. Klionsky,et al.  The variability of autophagy and cell death susceptibility , 2013, Autophagy.

[10]  M. Seishima,et al.  Resveratrol reverses remodeling in hearts with large, old myocardial infarctions through enhanced autophagy-activating AMP kinase pathway. , 2013, The American journal of pathology.

[11]  E. McNally,et al.  Genetic mutations and mechanisms in dilated cardiomyopathy. , 2013, The Journal of clinical investigation.

[12]  M. Seishima,et al.  Autophagy limits acute myocardial infarction induced by permanent coronary artery occlusion. , 2011, American journal of physiology. Heart and circulatory physiology.

[13]  M. Zou,et al.  Improvement of Cardiac Functions by Chronic Metformin Treatment Is Associated With Enhanced Cardiac Autophagy in Diabetic OVE26 Mice , 2011, Diabetes.

[14]  R. D. de Boer,et al.  Metformin improves cardiac function in a nondiabetic rat model of post-MI heart failure. , 2011, American journal of physiology. Heart and circulatory physiology.

[15]  V. Straub,et al.  δ-Sarcoglycan-deficient muscular dystrophy: from discovery to therapeutic approaches , 2011, Skeletal Muscle.

[16]  Yi Zhu,et al.  Metformin attenuates cardiac fibrosis by inhibiting the TGFbeta1-Smad3 signalling pathway. , 2010, Cardiovascular research.

[17]  M. Goddeeris,et al.  Sarcoglycan Complex , 2009, The Journal of Biological Chemistry.

[18]  M. Sugimachi,et al.  Metformin Prevents Progression of Heart Failure in Dogs: Role of AMP-Activated Protein Kinase , 2009, Circulation.

[19]  R. Shaw,et al.  LKB1 and AMP‐activated protein kinase control of mTOR signalling and growth , 2009, Acta physiologica.

[20]  S. Jha,et al.  Activation of AMP-Activated Protein Kinase by Metformin Improves Left Ventricular Function and Survival in Heart Failure , 2009, Circulation research.

[21]  M. Seishima,et al.  Functional significance and morphological characterization of starvation-induced autophagy in the adult heart. , 2008, The American journal of pathology.

[22]  Chengqun Huang,et al.  A method to measure cardiac autophagic flux in vivo , 2008, Autophagy.

[23]  Guido Kroemer,et al.  Autophagy in the Pathogenesis of Disease , 2008, Cell.

[24]  Masaaki Komatsu,et al.  Homeostatic Levels of p62 Control Cytoplasmic Inclusion Body Formation in Autophagy-Deficient Mice , 2007, Cell.

[25]  Yasushi Matsumura,et al.  The role of autophagy in cardiomyocytes in the basal state and in response to hemodynamic stress , 2007, Nature Medicine.

[26]  G. Takemura,et al.  Autophagic Degeneration and Death of Cardiomyocytes in Heart Failure , 2006, Autophagy.

[27]  Lin Yan,et al.  Autophagy in chronically ischemic myocardium. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[28]  H. Krumholz,et al.  Thiazolidinediones, Metformin, and Outcomes in Older Patients With Diabetes and Heart Failure: An Observational Study , 2005, Circulation.

[29]  A. Briguet,et al.  Histological parameters for the quantitative assessment of muscular dystrophy in the mdx-mouse , 2004, Neuromuscular Disorders.

[30]  H. Krumholz,et al.  Metformin and thiazolidinedione use in Medicare patients with heart failure. , 2003, JAMA.

[31]  K. Campbell,et al.  Muscular dystrophies involving the dystrophin-glycoprotein complex: an overview of current mouse models. , 2002, Current opinion in genetics & development.

[32]  Margaret S. Wu,et al.  Role of AMP-activated protein kinase in mechanism of metformin action. , 2001, The Journal of clinical investigation.

[33]  Takeshi Noda,et al.  LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing , 2000, The EMBO journal.

[34]  J. Towbin,et al.  Mutations in the Human δ-Sarcoglycan Gene in Familial and Sporadic Dilated Cardiomyopathy, a Disease of the Cytoskeleton and Sarcolemma , 2000 .

[35]  H. Sweeney,et al.  Differential requirement for individual sarcoglycans and dystrophin in the assembly and function of the dystrophin-glycoprotein complex. , 2000, Journal of cell science.

[36]  K. Campbell,et al.  Disruption of the Sarcoglycan–Sarcospan Complex in Vascular Smooth Muscle A Novel Mechanism for Cardiomyopathy and Muscular Dystrophy , 1999, Cell.

[37]  Nicolas Deconinck,et al.  Expression of full-length utrophin prevents muscular dystrophy in mdx mice , 1998, Nature Medicine.

[38]  K. Campbell,et al.  Animal Models for Muscular Dystrophy Show Different Patterns of Sarcolemmal Disruption , 1997, The Journal of cell biology.